Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1993 1
1994 3
1995 2
1996 4
1997 2
1999 1
2002 1
2004 2
2005 1
2008 6
2009 6
2010 2
2011 1
2012 1
2013 1
2016 2
2017 4
2018 1
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. Kater AP, et al. Among authors: mellink c. J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28. J Clin Oncol. 2020. PMID: 32986498
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Kater AP. Niemann CU, et al. Among authors: mellink chm. Blood. 2020 Oct 7:blood.2020008608. doi: 10.1182/blood.2020008608. Online ahead of print. Blood. 2020. PMID: 33027809 No abstract available.
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study.
Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, Van der Kevie-Kersemaekers AM, Posthuma H, Rodriguez-Vicente AE, Tran AN, Barbany G, Mansouri L, Gunnarsson R, Parker H, Van den Berg E, Bellido M, Davis Z, Wall M, Scarpelli I, Österborg A, Hansson L, Jarosova M, Ghia P, Poddighe P, Espinet B, Pospisilova S, Tam C, Ysebaert L, Nguyen-Khac F, Oscier D, Haferlach C, Schoumans J, Stevens-Kroef M, Eldering E, Stamatopoulos K, Rosenquist R, Strefford JC, Mellink C, Kater AP. Leeksma AC, et al. Among authors: mellink c. Haematologica. 2021 Jan 1;106(1):87-97. doi: 10.3324/haematol.2019.239947. Haematologica. 2021. PMID: 31974198 Free PMC article.
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, Evers LM, Croon-de Boer F, Schreurs J, van der Spek E, Visser H, Idink C, Wittebol S, Hoogendoorn M, Tonino SH, Mobasher M, Levin MD; HOVON CLL study group.. Kater AP, et al. Among authors: mellink ch. Blood Adv. 2018 Dec 26;2(24):3566-3571. doi: 10.1182/bloodadvances.2018019422. Blood Adv. 2018. PMID: 30552161 Free PMC article.
Generation and characterization of human iPSC lines SANi001-A and SANi002-A from mobilized peripheral blood derived megakaryoblasts.
Hansen M, Varga E, Wüst T, Mellink C, van der Kevie-Kersemaekers AM, von Lindern M, van den Akker E. Hansen M, et al. Among authors: mellink c. Stem Cell Res. 2017 Dec;25:42-45. doi: 10.1016/j.scr.2017.10.002. Epub 2017 Oct 12. Stem Cell Res. 2017. PMID: 29055227 Free article.
Generation and characterization of human iPSC line MML-6838-Cl2 from mobilized peripheral blood derived megakaryoblasts.
Hansen M, Varga E, Wüst T, Brouwer N, Beauchemin H, Mellink C, van der Kevie-Kersemaekers AM, Möröy T, van der Reijden B, von Lindern M, van den Akker E. Hansen M, et al. Among authors: mellink c. Stem Cell Res. 2017 Jan;18:26-28. doi: 10.1016/j.scr.2016.12.004. Epub 2016 Dec 10. Stem Cell Res. 2017. PMID: 28395797 Free article.
The PiGMaP consortium cytogenetic map of the domestic pig (Sus scrofa domestica).
Yerle M, Lahbib-Mansais Y, Mellink C, Goureau A, Pinton P, Echard G, Gellin J, Zijlstra C, De Haan N, Bosma AA, et al. Yerle M, et al. Among authors: mellink c. Mamm Genome. 1995 Mar;6(3):176-86. doi: 10.1007/BF00293009. Mamm Genome. 1995. PMID: 7749224 Review. No abstract available.
Generation and characterization of a human iPSC line SANi005-A containing the gray platelet associated heterozygous mutation p.Q287* in GFI1B.
Hansen M, Varga E, Wüst T, Mellink C, van der Kevie-Kersemaekers AM, Marneth AE, von Lindern M, van der Reijden B, van den Akker E. Hansen M, et al. Among authors: mellink c. Stem Cell Res. 2017 Dec;25:34-37. doi: 10.1016/j.scr.2017.10.008. Epub 2017 Oct 12. Stem Cell Res. 2017. PMID: 29055225 Free article.
Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.
van Andel H, Kocemba KA, de Haan-Kramer A, Mellink CH, Piwowar M, Broijl A, van Duin M, Sonneveld P, Maurice MM, Kersten MJ, Spaargaren M, Pals ST. van Andel H, et al. Among authors: mellink ch. Oncogene. 2017 Apr;36(15):2105-2115. doi: 10.1038/onc.2016.368. Epub 2016 Oct 24. Oncogene. 2017. PMID: 27775078
A novel MLL-SEPT2 fusion variant in therapy-related myelodysplastic syndrome.
Cerveira N, Santos J, Pinheiro M, Snijder S, van der Lelie H, Mellink CH, Teixeira MR. Cerveira N, et al. Among authors: mellink ch. Cancer Genet Cytogenet. 2008 Aug;185(1):62-4. doi: 10.1016/j.cancergencyto.2008.05.002. Cancer Genet Cytogenet. 2008. PMID: 18656699 No abstract available.
40 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback